Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. (Iovance Biotherapeutics (NASDAQ: IOVA)) is dedicated to the fight against cancer. The company, founded in 2007 and headquartered in the San Francisco Bay Area, aims to become the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The organization's pioneering approach harnesses the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Their lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. Iovance's TIL platform has demonstrated promising clinical data across multiple solid tumors. As it executes its commercial launch and advances research and development efforts, Iovance is adding to its talented team and building internal manufacturing capabilities. The company's Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia, and it also has a research site in Tampa, Florida. Iovance's last investment was a significant $211.00MPost-IPO Equity investment on 20 February 2024. Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission, available at https://ir.iovance.com/sec-filings. Iovance Biotherapeutics is active in the Biotechnology and Health Care industries.